Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for laser-refractory diabetic macular edema
2006-001182-41Phase 3Completed
- Sponsor
- Ass.Prof. Petros Sfikakis
- Start
- Nov 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of infliximab in diabetic macular edema (DME) (2 arms), sponsored by Ass.Prof. Petros Sfikakis. Primary endpoint: Best corrected visual acuity after 4 infliximab infusions. Started Nov 2006; status: completed.
02
Drugs
infliximab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2006-001182-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001182-41.